MCID: HYP263
MIFTS: 40

Hypersomnia malady

Categories: Neuronal diseases, Mental diseases

Aliases & Classifications for Hypersomnia

About this section

Aliases & Descriptions for Hypersomnia:

Name: Hypersomnia 49 68

Classifications:



Summaries for Hypersomnia

About this section
NINDS:49 Hypersomnia is characterized by recurrent episodes of excessive daytime sleepiness or prolonged nighttime sleep. Different from feeling tired due to lack of or interrupted sleep at night, persons with hypersomnia are compelled to nap repeatedly during the day, often at inappropriate times such as at work, during a meal, or in conversation. These daytime naps usually provide no relief from symptoms. Patients often have difficulty waking from a long sleep, and may feel disoriented. Other symptoms may include anxiety, increased irritation, decreased energy, restlessness, slow thinking, slow speech, loss of appetite, hallucinations, and memory difficulty. Some patients lose the ability to function in family, social, occupational, or other settings. Hypersomnia may be caused by another sleep disorder (such as narcolepsy or sleep apnea), dysfunction of the autonomic nervous system, or drug or alcohol abuse. In some cases it results from a physical problem, such as a tumor, head trauma, or injury to the central nervous system. Certain medications, or medicine withdrawal, may also cause hypersomnia. Medical conditions including multiple sclerosis, depression, encephalitis, epilepsy, or obesity may contribute to the disorder. Some people appear to have a genetic predisposition to hypersomnia; in others, there is no known cause. Typically, hypersomnia is first recognized in adolescence or young adulthood.

MalaCards based summary: Hypersomnia is related to idiopathic hypersomnia and recurrent hypersomnia, and has symptoms including decreased libido, fatigue and hypersomnia with sleep apnea. An important gene associated with Hypersomnia is HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1), and among its related pathways are Cytokines and Inflammatory Response and CTLA4 Signaling. Affiliated tissues include brain, testes and heart.

Wikipedia:71 Hypersomnia, or hypersomnolence, is a neurological disorder of excessive time spent sleeping or... more...

Related Diseases for Hypersomnia

About this section

Diseases in the Hypersomnia family:

Recurrent Hypersomnia

Diseases related to Hypersomnia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 86)
idRelated DiseaseScoreTop Affiliating Genes
1idiopathic hypersomnia12.4
2recurrent hypersomnia12.2
3idiopathic hypersomnia without long sleep time12.0
4idiopathic hypersomnia with long sleep time11.9
5kleine-levin hibernation syndrome11.0
6myotonic dystrophy 210.8
7dystonia, dopa-responsive, due to sepiapterin reductase deficiency10.8
8fruit allergy10.7HLA-DQB1, HLA-DRB1
9idiopathic juxtafoveal retinal telangiectasia10.7HCRT, HLA-DQB1
10wolffian duct adenocarcinoma10.7HLA-DQB1, HLA-DRB1
11quinquaud's decalvans folliculitis10.7HLA-DQB1, HLA-DRB1
12parsonage turner syndrome10.7HLA-DQB1, HLA-DRB1
13pediatric systemic lupus erythematosus10.7HLA-DQB1, HLA-DRB1
14myopathy-growth delay-intellectual disability-hypospadias syndrome10.7HLA-DQB1, HLA-DRB1
15vitreoretinochoroidopathy dominant10.7HLA-DQB1, HLA-DRB1
16krieble bixler syndrome10.6HLA-DQB1, HLA-DRB1
17spondylarthropathy10.6HLA-DQB1, HLA-DRB1
18mitochondrial encephalomyopathy10.6HLA-DQB1, HLA-DRB1
19rheumatic myocarditis10.6HLA-DQB1, HLA-DRB1
20ovarian papillary cystadenoma10.6HLA-DQB1, HLA-DRB1
21nebulin-related early-onset distal myopathy10.6HLA-DQB1, HLA-DRB1
22purpura fulminans10.6HLA-DQB1, HLA-DRB1
23lymphocytic colitis10.6HLA-DQB1, HLA-DRB1
24autoinflammation, lipodystrophy, and dermatosis syndrome10.6HLA-DQB1, HLA-DRB1
25peripheral t-cell lymphoma10.5HLA-DQB1, HLA-DRB1
26foster-kennedy syndrome10.5HLA-DQB1, HLA-DRB1
27thrombocytopenia due to platelet alloimmunization10.5HLA-DQB1, HLA-DRB1
28orbit alveolar rhabdomyosarcoma10.5HLA-DQB1, HLA-DRB1
29narcolepsy10.5
30lipodermatosclerosis10.4HLA-DQB1, HLA-DRB1
31x-linked congenital generalized hypertrichosis10.4HLA-DQB1, HLA-DRB1
32idiopathic central precocious puberty10.4HLA-DQB1, HLA-DRB1
33aseptic osteitis10.3HLA-DQB1, HLA-DRB1
34sleep apnea10.2
35glutathionuria10.1HCRT, HLA-DQB1
36parkinson disease, late-onset10.1CYP2D6, HCRT, PARK2, SPR
37myotonic dystrophy10.0
38sleep disorder9.9
39prader-willi syndrome9.9
40brain injury9.9
41traumatic brain injury9.9
42neuronitis9.9
43obstructive sleep apnea9.8
44mood disorder9.8
45acute disseminated encephalomyelitis9.8
46encephalitis9.8
47encephalopathy9.8
48obesity9.7
49bipolar disorder9.7
50insulinoma9.7

Graphical network of the top 20 diseases related to Hypersomnia:



Diseases related to hypersomnia

Symptoms & Phenotypes for Hypersomnia

About this section

UMLS symptoms related to Hypersomnia:


decreased libido, fatigue, hypersomnia with sleep apnea, other hypersomnia, sleep disturbances, decrease in appetite, excessive daytime sleepiness - normal night sleep, excessive day and night-time sleepiness, postviral excessive daytime sleepiness, excess daytime sleepiness with sleep paralysis, oversleeps, excessive daytime somnolence, sleeplessness, [d]sleep disturbances (& [hypersomnia] or [insomnia]), symptoms, insomnia with sleep apnea, unspecified, hypersomnia with sleep apnea, unspecified, disruption of 24 hour sleep wake cycle, unspecified, hypersomnia: [transient] or [nos], infant sleeping more than 4-5 hours at a time, depression accompanied by sleeping more, sleeping much more than usual, daytime somnolence, hypersomnia due to medical condition, daytime hypersomnia

Drugs & Therapeutics for Hypersomnia

About this section

Drugs for Hypersomnia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 84)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Modafinilapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 119568693-11-84236
Synonyms:
Dea No. 1680
Modafinil
Modafinil [USAN:INN]
Modafinil [Usan:Inn]
Modafinilo
Modafinilo [Spanish]
 
Modafinilum
Modafinilum [Latin]
Moderateafinil
Modiodal
Provigil
Sparlon
modafinil
2
Armodafinilapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1195112111-43-0
Synonyms:
 
(–)-2-[(R)-(diphenylmethyl)sulfinyl]acetamide
R-modafinil
3
CitalopramapprovedPhase 450359729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
4
BupropionapprovedPhase 431934841-39-9, 34911-55-2444
Synonyms:
( -)-2-(tert-Butylamino)-3'-chloropropiophenone
( -)-2-(tert-Butylamino)-3'-chlorpropiophenon
(+-)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone
(+-)-Bupropion
.alpha.-(tert-Butylamino)-m-chloropropiophenone
1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]propan-1-one
2-(Tert-Butylamino)-3'-chloropropiophenone
2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one
34841-36-6 (hydrochloride)
34841-39-9
34911-55-2
AB00053756
AC-197
AC1L198Y
AMFEBUTAMONE HCl
Amfebutamon
Amfebutamona
Amfebutamona [INN-Spanish]
Amfebutamone
Amfebutamonum
Amfebutamonum [INN-Latin]
BPBio1_000042
BRD-A05186015-003-05-7
BRN 2101062
BSPBio_000038
BSPBio_002247
Bupropion (INN)
Bupropion (Old RN)
Bupropion (USAN)
Bupropion Hcl
Bupropion SR
Bupropion [INN:BAN]
Bupropion hydrocloride
C06860
CHEBI:3219
CHEMBL894
CID444
CPD000472526
D07591
DB01156
DivK1c_007050
Elont
 
HMS2051G10
HMS2089G14
Jsp006301
KBio1_001994
KBio2_002143
KBio2_004711
KBio2_007279
KBio3_001467
KBioGR_001168
KBioSS_002143
L000725
LS-122817
Lopac0_000166
MLS001424015
MolPort-003-845-432
NCGC00015122-06
NCGC00089751-02
NCI60_002714
NSC315851
Prestwick0_000249
Prestwick1_000249
Prestwick2_000249
Prestwick3_000249
SAM001246699
SMR000472526
SPBio_001817
SPBio_002257
SpecPlus_000954
Spectrum2_001659
Spectrum3_000644
Spectrum4_000614
Spectrum5_001406
Spectrum_001663
TL8002604
UNII-01ZG3TPX31
Wellbatrin
Wellbutrin
Wellbutrin SR
Wellbutrin XL
Zyban
alpha-(tert-butylamino)-m-chloropropiophenone
amfebutamonum
bupropion
5
DopamineapprovedPhase 4, Phase 2, Phase 1375951-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
6Cytochrome P-450 CYP3A InducersPhase 4, Phase 3, Phase 2, Phase 11101
7Peripheral Nervous System AgentsPhase 4, Phase 3, Phase 2, Phase 122776
8Central Nervous System StimulantsPhase 4, Phase 3, Phase 2, Phase 12132
9Wakefulness-Promoting AgentsPhase 4, Phase 3, Phase 2, Phase 1192
10Antidepressive AgentsPhase 4, Phase 22666
11Psychotropic DrugsPhase 4, Phase 26279
12Neurotransmitter AgentsPhase 4, Phase 2, Phase 3, Phase 117734
13ParasympatholyticsPhase 41050
14Neurotransmitter Uptake InhibitorsPhase 4, Phase 2, Phase 13464
15Serotonin AgentsPhase 4, Phase 23102
16Serotonin Uptake InhibitorsPhase 41570
17Muscarinic AntagonistsPhase 41134
18
SerotoninPhase 4, Phase 2356650-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
19Cytochrome P-450 Enzyme InhibitorsPhase 4, Phase 23822
20Autonomic AgentsPhase 4, Phase 2, Phase 19774
21Antiparkinson AgentsPhase 4, Phase 21527
22Antidepressive Agents, Second-GenerationPhase 41287
23Dopamine Uptake InhibitorsPhase 4, Phase 2, Phase 11305
24Cholinergic AgentsPhase 43846
25Cholinergic AntagonistsPhase 41658
26Cytochrome P-450 CYP2D6 InhibitorsPhase 4716
27Dopamine AgentsPhase 4, Phase 2, Phase 13759
28AnestheticsPhase 49001
29
Morphineapproved, investigationalPhase 396057-27-25288826
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(-)-Morphine
(-)Morphine sulfate
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(−)-morphine
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
47106-99-0
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
8053-16-5
85201-37-2
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
CID5288826
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
DepoDur
Depodur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
HSDB 2134
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
 
Infumorph
Kadian
LS-91748
M-Eslon
M.O.S
MOI
MORPHINE SULFATE
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
MS Contin
MS/L
MS/S
MSIR
Meconium
MolPort-003-849-273
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine Sulfate
Morphine [BAN]
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
Ms Emma
NSC11441
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
RMS
RMS Uniserts
Rescudose
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
UNII-76I7G6D29C
Unkie
l-Morphine
morfina
morphine
nchembio.317-comp1
nchembio.64-comp1
30
HistamineapprovedPhase 3, Phase 2103475614-87-8, 51-45-6774
Synonyms:
.beta.-Imidazolyl-4-ethylamine
1H-Imidazole-4-ethanamine
1H-Imidazole-5-ethanamine
1avn
1qft
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(1H-imidazol-4-yl)ethan-1-amine
2-(1H-imidazol-5-yl)ethanamine
2-(3H-Imidazol-4-yl)-ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-yl-Ethylamine
2-Imidazol-4-ylethylamine
2-[4-Imidazolyl]ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-Imidazoleethylamine
5-Imidazoleethylamine
51-45-6
53290_FLUKA
64422-25-9
924364-91-0
AC-13185
AC1L19ZT
AC1Q54BV
AC1Q54BW
AKOS000274386
ALBB-005968
BCBcMAP01_000250
BSPBio_001117
BSPBio_002124
Bio1_000487
Bio1_000976
Bio1_001465
Bio2_000389
Bio2_000869
C00388
CCRIS 6535
CHEBI:18295
CHEMBL90
CID774
D08040
DivK1c_000308
EINECS 200-100-6
Eramin
Ergamine
Ergotidine
F411C768-A159-4FC0-A195-291A08BB03AA
Free histamine
H7125_SIGMA
HMS1362G19
HMS1792G19
HMS1990G19
HSDB 3338
HSM
Histamine
Histamine (DCF)
Histamine Base
Histamine [USAN]
Histamine, Free Base
Histaminum
 
Histaminum (TN)
IDI1_000308
IDI1_002144
Imidazole-4-ethylamine
Istamina
Istamina [Italian]
KBio1_000308
KBio2_000457
KBio2_001325
KBio2_003025
KBio2_003893
KBio2_005593
KBio2_006461
KBio3_000853
KBio3_000854
KBio3_001344
KBioGR_000457
KBioGR_001580
KBioSS_000457
KBioSS_001325
L-Histamin base
L-Histamine
L-histamine
L000292
LS-75835
Lopac-H-7250
Lopac0_000595
MLS000069447
MolPort-001-785-597
MolPort-002-042-264
NCGC00015513-01
NCGC00015513-08
NCGC00093371-02
NCGC00093371-03
NCGC00093371-04
NCGC00093371-05
NINDS_000308
NSC 33792
NSC33792
SDCCGMLS-0066601.P001
SMP1_000151
SMR000059091
SPBio_000729
ST073926
STK346752
STOCK5S-55669
Spectrum2_000665
Spectrum3_000452
Spectrum4_000960
Spectrum5_000796
Spectrum_000845
Theramine
UNII-820484N8I3
WLN: T5M CNJ D2Z
ZERO/004089
[3H]histamine
b-Imidazolyl-4-ethylamine
beta-Aminoethylglyoxaline
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
beta-aminothethylglyoxaline
bmse000744
histamine
nchembio.87-comp54
nchembio714-comp1
31
Histamine PhosphateapprovedPhase 3, Phase 2103351-74-165513
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
 
EINECS 200-118-4
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
Histaminum
LS-78569
UNII-QWB37T4WZZ
32
Dehydroepiandrosteroneapproved, nutraceuticalPhase 2, Phase 39553-43-09860744
Synonyms:
(+)-Dehydroisoandrosterone
(3-beta)-3-Hydroxyandrost-5-en-17-one
(3beta)-3-hydroxy-Androst-5-en-17-one
(3beta,16alpha)-3,16-dihydroxy-androst-5-en-17-one
17-Chetovis
17-Hormoforin
3-beta-Hydroxy-5-androsten-17-one
3-beta-Hydroxyandrost-5-en-17-one
3b-Hydroxy-D5-androsten-17-one
3b-Hydroxyandrost-5-en-17-one
3beta-Hydroxy-D5-androsten-17-one
3beta-Hydroxyandrost-5-en-17-one
3beta-hydroxy-5-androsten-17-one
3beta-hydroxy-Androst-5-en-17-one
3beta-hydroxyandrost-5-en-17-one
3β-hydroxyandrost-5-en-17-one
5,6-Dehydroisoandrosterone
5,6-Didehydroisoandrosterone
5-Androsten-3-beta-ol-17-one
5-Androsten-3b-ol-17-one
5-Androsten-3beta-ol-17-one
5-DHEA
5-Dehydro-Epiandrosterone
 
5-Dehydroepiandrosterone
5-dehydroepiandrosterone
Andrestenol
Androst-5-ene-3b-ol-17-one
Androst-5-ene-3beta-ol-17-one
Androsten-3beta-ol-17-one
Androstenolone
Astenile
D5-Androsten-3b-ol-17-one
D5-Androsten-3beta-ol-17-one
DHEA
Deandros
Dehydro-epi-androsterone
Dehydroandrosterone
Dehydroepiandrosterone
Dehydroisoandrosterone
Diandron
Diandrone
Hydroxyandrostenone
Prasterona
Prasterone
Prasteronum
Prestara
Psicosterone
trans-Dehydroandrosterone
33
Caffeineapproved, NutraceuticalPhase 2, Phase 338058-08-22519
Synonyms:
07E4FB58-FD79-4175-8E3D-05BF96954522
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-Trimethylxanthine
1,3,7-trimethyl-2,6-dioxopurine
1,3,7-trimethylpurine-2,6-dione
1,3,7-trimethylxanthine
1-3-7-TRIMETHYLXANTHINE
1-Methyl-Theobromine
1-methyltheobromine
137X
1gfz
1l5q
1l7x
27602_FLUKA
2a3b
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
3,7-dihydro-1,3,7-trimethyl-1H-purine
5-26-13-00558 (Beilstein)
58-08-2
7-Methyl Theophylline
7-Methyltheophylline
7-methyltheophylline
71701-02-5
75035_FLUKA
95789-13-2
A.S.A. and Codeine Compound
AC-12774
AC1L1DV2
AC1Q3Z23
ACon1_000085
AI3-20154
AKOS000121334
Alert-Pep
Alert-pep
Anacin Maximum Strength
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anhydrous caffeine (TN)
Anoquan
BIDD:ER0554
BIDD:GT0632
BIDD:PXR0172
BIM-0050216.0001
BRD-K02404261-001-02-7
BRD-K02404261-001-03-5
BRN 0017705
BSPBio_001921
Berlin-Chemie Brand of Caffeine
Bio-0579
Bio1_000473
Bio1_000962
Bio1_001451
Bristol-Myers Squibb Brand of Caffeine
C 0750
C07481
C0750_SIAL
C1778_SIAL
C2042
C6035_FLUKA
C6035_SIGMA
C7731_SIAL
C8960_SIAL
CCRIS 1314
CFF
CHEBI:27732
CHEMBL113
CID2519
CU-01000012617-3
Cafamil
Cafcit
Cafecon
Cafeina
Cafergot
Cafeína
Caffedrine
Caffedrine Caplets
Caffein
Caffeina
Caffeina [Italian]
Caffeine (USP)
Caffeine (natural)
Caffeine Pure
Caffeine [BAN:JAN]
Caffeine solution
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeine, anhydrous
Caffeine, synthetic
Caffeinum
Caffine
Cafipel
Caféine
Coffein
Coffein [German]
Coffeine
Coffeinum
Coffeinum N
Coffeinum Purrum
Compound 65
D002110
D00528
DB00201
DHC Plus
DHCplus
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
DivK1c_000730
Durvitan
EINECS 200-362-1
EU-0100228
Eldiatric C
Enerjets
Ercatab
Esgic
Esgic-Plus
FEMA No. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline Brand of Caffeine
Guaranine
HMS1920I09
HMS2091O11
HMS502E12
HSDB 36
Hycomine
Hycomine Compound
I14-4386
 
IDI1_000730
Invagesic
Invagesic Forte
KBio1_000730
KBio2_001781
KBio2_004349
KBio2_006917
KBio3_001141
KBioGR_002325
KBioSS_001781
Keep Alert
Kofein
Kofein [Czech]
Koffein
Koffein [German]
L000155
LS-237
Lanorinal
Lopac-C-0750
Lopac0_000228
MEGxp0_001350
MLS001055341
MLS001056714
MLS001066409
Mateina
Mateína
Maximum Strength Snapback Stimulant Powders
Medigesic Plus
Merck dura Brand of Caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Midol Maximum Strength
Migergot
Miudol
MolMap_000054
MolPort-000-730-850
Monohydrate Caffeine
Monomethyl Derivative of Theophylline
Monomethyl derivative of Theophylline
NCGC00015208-01
NCGC00015208-02
NCGC00015208-04
NCGC00015208-14
NCGC00090699-01
NCGC00090699-02
NCGC00090699-03
NCGC00090699-04
NCGC00090699-05
NCGC00090699-06
NCGC00090699-07
NCGC00090699-08
NCGC00090699-09
NCGC00168808-01
NCGC00168808-02
NCI-C02733
NCIOpen2_008255
NINDS_000730
NSC 5036
NSC5036
Natural Caffeinum
Nix Nap
No Doz
No-Doz
Nodaca
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
Organex
Orphengesic
Orphengesic Forte
P-A-C Analgesic Tablets
PDSP1_001016
PDSP1_001235
PDSP2_001000
PDSP2_001219
Passauer Brand of Caffeine
Pep-Back
Percoffedrinol N
Percutafeine
Phensal
Pierre Fabre Brand of Caffeine
Probes1_000150
Probes2_000128
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick Pep
Quick-Pep
Refresh'n
Republic Drug Brand of Caffeine
SDCCGMLS-0064595.P001
SDCCGMLS-0064595.P002
SK 65 Compound
SK-65 Compound
SMR000326667
SPBio_001222
SPECTRUM1500155
STK177283
Seid Brand of Caffeine
Spectrum2_001261
Spectrum3_000321
Spectrum4_001782
Spectrum5_000423
Spectrum_001301
Stim
Synalgos-Dc
TNP00310
Thein
Theine
Theobromine ME
Theobromine Me
Theophylline ME
Theophylline Me
Theophylline, 7-methyl
Thompson Brand 1 of Caffeine
Thompson Brand 2 of Caffeine
Tirend
Tri-Aqua
Triad
UNII-3G6A5W338E
Ultra Pep-Back
Vivarin
W222402_ALDRICH
WLN: T56 BN DN FNVNVJ B1 F1 H1
Wake-Up
Wigraine
Xanthine, 1,3,7-trimethyl
ZINC00001084
bmse000206
cafeine
caffeine
caffenium
component of Cafergot
nchembio.243-comp7
nchembio.63-comp5
nchembio774-comp2
teina
teína
34Analgesics, OpioidPhase 33091
35AnalgesicsPhase 311287
36Central Nervous System DepressantsPhase 3, Phase 212806
37NarcoticsPhase 33486
38Histamine H3 AntagonistsPhase 310
39Phosphodiesterase InhibitorsPhase 2, Phase 31254
40Purinergic P1 Receptor AntagonistsPhase 2, Phase 3348
41Adjuvants, ImmunologicPhase 2, Phase 32484
42DHEA (Dehydroepiandrosterone)NutraceuticalPhase 2, Phase 395
43
Diethylpropionapproved, illicitPhase 1, Phase 2290-84-6, 134-80-57029
Synonyms:
(+-)-Diethylpropion
(+-)-diethylpropion
(±)-diethylpropion
1-Phenyl-2-diethylamino-1-propanone
1-phenyl-2-diethylamino-1-propanone
2-(Diethylamino)-1-phenyl-1-propanone
2-(Diethylamino)propiophenone
2-(diethylamino)-1-phenylpropan-1-one
2-Diethylaminopropiophenone
4-14-00-00144 (Beilstein Handbook Reference)
90-84-6
AC-13099
AC1L1NUD
Adiposon
Amfepramon
Amfepramone
Amfepramone (INN)
Amfepramone HCL
Amfepramone [INN]
Amfepramone hydrochloride
Amfepramonum
Amfepramonum [INN-Latin]
Amphepramon
Amphepramone
Amphepramonum hydrochloride
Anfamon
Anfepramona
Anfepramona [INN-Spanish]
Anorex
BRN 2804400
C06954
C13H19NO
CHEBI:4530
CID7029
Cegramine
D07444
DB00937
 
DEA No. 1610
DIETHYLPROPION
Danylen
Derfon
Diethylcathinone
Diethylpropion
Diethylpropion (BAN)
Diethylpropion HCL
Diethylpropione
Diethylpropione hydrochloride
Dobesin
EINECS 202-019-1
Fenyl-(1-diethylaminoethyl)keton
Fenyl-(1-diethylaminoethyl)keton [Czech]
Frekentine
HSDB 3059
Keramik
Keramin
LS-125137
Magrene
Modulor
MolPort-001-783-471
Neobes
Nopropiophenone
Obesitex
Parabolin
Phepranon
Prefamone
Regenon
Reginon
Silutin
Tenuate hydrochloride
Tepanil
Tylinal
UNII-Q94YYU22B8
UR 1423
alpha-Benzoyltriethylamine
alpha-Diethylaminopropiophenone
44
Dextroamphetamineapproved, illicitPhase 2, Phase 17051-64-95826
Synonyms:
(+)-(S)-Amphetamine
(+)-(S)-amphetamine
(+)-(s)-amphetamine
(+)-Amphetamine
(+)-Phenaminum
(+)-alpha-Methylphenethylamine
(+)-alpha-Methylphenylethylamine
(+)-alpha-methylphenethylamine
(+)-alpha-methylphenylethylamine
(+)-amphetamine
(+)-phenaminum
(+/-)-Benzedrine
(+/-)-Desoxynorephedrine
(+/-)-beta-Phenylisopropylamine
(2S)-(+)-Amphetamine
(2S)-1-phenylpropan-2-amine
(AlphaS)-alpha-methylbenzeneethanamine
(S)-(+)-Amphetamine
(S)-(+)-beta-Phenylisopropylamine
(S)-1-Phenyl-2-aminopropane
(S)-1-Phenyl-2-propanamine
(S)-1-Phenyl-2-propylamine
(S)-1-phenyl-2-aminopropane
(S)-1-phenyl-2-propylamine
(S)-Amphetamine
(S)-alpha-Methylbenzeneethanamine
(S)-alpha-Methylphenethylamine
(S)-alpha-Phenylethylamine
(S)-alpha-methylbenzeneethanamine
(S)-amphetamine
(alphaS)-alpha-methylbenzeneethanamine
(s)-(+)-amphetamine
(s)-(+)-beta-phenylisopropylamine
(s)-alpha-methylbenzeneethanamine
(s)-alpha-methylphenethylamine
(s)-alpha-phenylethylamine
(s)-amphetamine
1-Methyl-2-phenylethylamine
4-12-00-02587 (Beilstein Handbook Reference)
51-64-9
AC1L1L85
Amsustain
BRN 2205872
Benzedrine
Benzeneethanamine, alpha-methyl-, (aS)- (9CI)
C07884
CHEBI:4469
CHEMBL612
CID5826
D-(+)-Amphetamine
D-(+)-amphetamine
D-(S)-Amphetamine
D-(s)-amphetamine
D-1-Phenyl-2-aminopropan
D-1-Phenyl-2-aminopropane
D-2-Amino-1-phenylpropane
D-AM
D-Amphetamine
D-alpha-methylphenethylamine
D-am
D-amphetamine
D03740
DB00182
DB01576
 
DEA No. 1100
Dephadren
Desamfetamina
Desamfetamina [DCIT]
Desoxyn
Dexacaps
Dexadrine
Dexamfetamina
Dexamfetamina [INN-Spanish]
Dexamfetamina [inn-spanish]
Dexamfetamine
Dexamfetamine (INN)
Dexamfetaminum
Dexamfetaminum [INN-Latin]
Dexamfetaminum [inn-latin]
Dexamphetamine
Dexamphetaminum
Dexamphetaminum [INN-Latin]
Dexamphetaminum [inn-latin]
Dexanfetamina
Dexanfetamina [INN-Spanish]
Dexanfetamina [inn-spanish]
Dexedrine
Dexedrine Spansule
Dexidrine
Dextro-Amphetamine Sulfate
Dextroamphetamine
Dextroamphetamine (USAN)
Dextroamphetamine [USAN]
Dextroamphetamine resin complex
Dextroamphetamine sulfate
Dextrostat
EINECS 200-112-1
Fenylo-izopropylaminyl
HSDB 3055
Isoamycin
LS-103617
LS-187774
MolPort-004-285-839
NCGC00168247-01
NSC 73713
PDSP1_001511
PDSP2_001495
Phenethylamine, alpha-methyl-, (+)- (8CI)
Propisamine
Psychedrine
Raphetamine
Rhinalator
S(+)-Amphetamine
S(+)-amphetamine
Simpatedrin
Sympamin
Sympamine
Sympatedrine
UNII-TZ47U051FI
Weckamine
alpha-Methylphenethylamine, d-form
beta-phenyl-isopropylamine
d-1-Phenyl-2-aminopropan [German]
d-amphetamine
dexamphetamine
dextro-Amphetamine
dextroamphetamine
dl-1-Phenyl-2-aminopropane
dl-Amphetamine
dl-Benzedrine
45
Minocyclineapproved, investigationalPhase 222410118-90-85281021
Synonyms:
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione
(4S,4AS,5AR,12AS)-4,7-BIS(DIMETHYLAMINO)-3,10,12,12A-TETRAHYDROXY-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE
(4S,4AS,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
10118-90-8
13614-98-7 (mono-hydrochloride)
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
4708-96-7
7-Dimethylamino-6-demethyl-6-deoxytetracycline
AC1NQXWM
BRN 3077644
Bio-0062
Borymycin
C07225
C23H27N3O7
CHEBI:50694
CHEBI:529981
CHEMBL1434
CHEMBL259172
CID5281021
CL 59806
CRL-1605 & Minocycline
D05045
HMS2090D03
HSDB 3130
 
LMPK07000002
LS-93850
Lactoferrin B & Minocycline
Lactoferrin H & Minocycline
MINO
MIY
Minociclina
Minociclina [INN-Spanish]
Minociclinum
Minocin
Minocin (Hydrochloride)
Minocline
Minocyclin
Minocycline (USAN/INN)
Minocycline Monohydrochloride
Minocycline [USAN:BAN:INN]
Minocyclinum
Minocyclinum [INN-Latin]
NCGC00178854-01
NSC 141993
NSC141993
UNII-FYY3R43WGO
Vectrin (Hydrochloride)
minociclinum
minocycline
nchembio.559-comp1
46
Riluzoleapproved, investigationalPhase 2631744-22-55070
Synonyms:
1744-22-5
2-Amino-6-(trifluoromethoxy)-benzothiazole
2-Amino-6-(trifluoromethoxy)benzothiazole
2-Amino-6-trifluoro- methoxybenzothiazole
2-amino-6-(trifluoromethoxy)-1,3-benzothiazole
2-amino-6-(trifluoromethoxy)benzo[d]thiazole
2-amino-6-(trifluoromethoxyl)benzothiazole
2-amino-6-trifluoromethoxybenzothiazole
6-(trifluoromethoxy)-1,3-benzothiazol-2-amine
6-(trifluoromethoxy)benzo[d]thiazol-2-amine
6-Trifluoromethoxy-benzothiazol-2-ylamine
6-trifluoromethoxybenzothiazole-2-yl-amine
AC-730
AC1L1JJL
AC1Q530H
AKOS000265071
ALBB-006046
Amino-2 trifluoromethoxy-6 benzothiazole
Amino-2 trifluoromethoxy-6 benzothiazole [French]
BB_SC-4839
BF-37
BIDD:GT0055
BPBio1_000037
BPBio1_000837
BRD-K21283037-001-02-5
BRD-K21283037-003-03-9
BSPBio_000033
Bio1_000416
Bio1_000905
Bio1_001394
Biomol-NT_000245
C07937
C8H5F3N2OS
CHEMBL744
CID5070
D00775
DB00740
EU-0101064
FT-0082997
HMS1773G08
HMS2089O19
HMS2094G07
I01-2084
LS-40688
 
Lopac-R-116
Lopac0_001064
MLS000069369
MolPort-000-151-262
NCGC00015882-01
NCGC00015882-02
NCGC00015882-03
NCGC00015882-07
NCGC00015882-11
NCGC00023141-02
NCGC00023141-04
NCGC00023141-05
NCGC00023141-06
PK-26124
PK-26124, RP-54274, Rilutek, Riluzole
Prestwick-03A08
Prestwick0_000167
Prestwick1_000167
Prestwick2_000167
Prestwick3_000167
R-116
R116_SIGMA
RP 54274
RP-54274
Rilutek
Rilutek (TN)
Riluzol
Riluzol [INN-Spanish]
Riluzole
Riluzole (JAN/USAN/INN)
Riluzole HCl
Riluzole [USAN:INN]
Riluzolum
Riluzolum [INN-Latin]
S1614_Selleck
SMR000058231
SPBio_000599
SPBio_001954
STK503686
Spectrum2_000550
Tocris-0768
UNII-7LJ087RS6F
ZERO/001785
ZINC00006481
riluzole
47
MentholapprovedPhase 223532216-51-516666
Synonyms:
(−
()-Menthol
(+)-Neo-menthol
(+)-p-Menthan-3-ol
(+-)-(1R*,3R*,4S*)-Menthol
(+-)-Menthol
(+/-)-Menthol
(+/-)-p-Menthan-3-ol
(-)-(1R,3R,4S)-Menthol
(-)-Menthyl alcohol
(-)-menthol
(-)-p-Menthan-3-ol
(-)-trans-p-Menthan-cis-ol
(1R)-(-)-Menthol
(1R,2S,5R)-(-)-menthol
(1R,2S,5R)-Menthol
(1R,3R,4S)-(-)-MENTHOL
(1R,3R,4S)-(-)-Menthol
(1R-(1-alpha,2-beta,5-alpha))-5-Methyl-2-(1-methylethyl)cyclohexanol
(1S, 2S, 5R)-(+)-Neomenthol
(1S,2R,5R)-(+)-Isomenthol
(1S,2R,5S)-(+)-Menthol
(1S,2R,5S)-Menthol
(1alpha,2beta,5alpha)-5-Methyl-2(1-methylethyl)cyclohexanol
(1r,2s,5r)-(-)-menthol
(L)-MENTHOL
(R)-(-)-Menthol
(r)-(-)-menthol
)-Menthol
--MENTHOL
1-Menthol
1490-04-6
15356-60-2
15356-70-4
15785_RIEDEL
15785_SIAL
19863P
2-Isopropyl-5-methylcyclohexanol
20747-49-3
2216-51-5
3-p-Menthol
4-Isopropyl-1-methylcyclohexan-3-ol
491-02-1
5-Methyl-2-(1-methylethyl)-cyclohexanol
5-Methyl-2-(1-methylethyl)cyclohexanol
5-methyl-2-(propan-2-yl)cyclohexanol
5-methyl-2-propan-2-ylcyclohexan-1-ol
551376_ALDRICH
551376_FLUKA
588733_ALDRICH
613290_ALDRICH
613290_FLUKA
63660_FLUKA
63670_ALDRICH
63670_FLUKA
63975-60-0
6C6A4A8C-A054-468C-A1F0-F29E39838CF2
89-78-1
98167-53-4
AC1L1B2E
AC1L28FR
AC1Q1NQ2
AC1Q2QQM
AI3-08161
AI3-52408
AKOS000119740
AR-1J3337
BB_NC-0057
BRN 1902288
BRN 3194263
BSPBio_003062
C00400
C10H20O
CCRIS 3728
CCRIS 375
CCRIS 4666
CCRIS 9231
CHEBI:15409
CHEBI:545611
CHEMBL256087
CHEMBL470670
CID1254
CID16666
Caswell No. 540
D-(-)-Menthol
D-p-Menthan-3-ol
D00064
D008610
D04849
D04918
DB00825
DivK1c_000820
EINECS 201-939-0
EINECS 207-724-8
EINECS 216-074-4
EINECS 218-690-9
EINECS 239-387-8
EINECS 239-388-3
EPA Pesticide Chemical Code 051601
FEMA No. 2665
Fisherman's friend lozenges
Fisherman's friend lozenges (TN)
HMS1922G13
HMS2092L14
HMS502I22
 
HSDB 5662
HSDB 593
Headache crystals
Hexahydrothymol
I06-1216
I14-7371
IDI1_000820
KBio1_000820
KBio2_000785
KBio2_003353
KBio2_005921
KBio3_002562
KBioSS_000785
L-(-)-Menthol
L-(-)-menthol
L-Menthol
L-menthol
LMPR0102090001
LS-2353
LS-57201
LS-886
LS-89531
LS-89533
Levomenthol
Levomenthol [INN:BAN]
Levomentholum
Levomentholum [INN-Latin]
Levomentol
M0321
M0545
M2772_SIAL
MENTHOL
MLS002207256
Menthacamphor
Menthol
Menthol (USP)
Menthol (VAN)
Menthol natural
Menthol natural, brazilian
Menthol racemic
Menthol racemique
Menthol racemique [French]
Menthol solution
Menthol, (1alpha,2beta,5alpha)-Isomer
Menthomenthol
Menthyl alcohol
MolPort-000-849-729
MolPort-001-793-392
NCGC00159382-02
NCGC00159382-03
NCGC00164247-01
NCGC00164247-02
NCI-C50000
NINDS_000820
NOOLISFMXDJSKH-KXUCPTDWBX
NSC 2603
NSC 62788
NSC2603
NSC62788
Neoisomenthol
Peppermint camphor
RACEMIC MENTHOL U.S.P.
Racementhol
Racementhol [INN:BAN]
Racementholum
Racementholum [INN-Latin]
Racementol
Racementol [INN-Spanish]
Racemic menthol
Robitussin Cough Drops
SDCCGMLS-0066659.P001
SMR001306785
SPBio_000869
SPECTRUM1503134
STK802468
Spectrum2_000855
Spectrum3_001561
Spectrum5_001060
Spectrum_000305
Tra-kill tracheal mite killer
U.S.P. Menthol
U.S.p. Menthol
UNII-BZ1R15MTK7
UNII-L7T10EIP3A
UNII-YS08XHA860
W266507_ALDRICH
W266523_ALDRICH
W266590_ALDRICH
WLN: L6TJ AY1&1 BQ D1
WLN: L6TJ AY1&1 DQ D1 -L
ZINC01482164
cis-1 ,3-trans-1,4-(+-)-menthol
cis-1,3-trans-1,4-(+-)-menthol
d,l-Menthol
d-Menthol
d-Neomenthol
dl-3-p-Menthanol
dl-Menthol
dl-Menthol (JP15)
l-(-)-Menthol
l-Menthol
l-Menthol (JP15)
l-Menthol (TN)
l-Menthol (natural)
nchembio862-comp1
p-Menthan-3-ol
rac-Menthol
48
BetahistineapprovedPhase 2165638-76-62366
Synonyms:
2-(beta-Methylaminoethyl)pyridine
2-[2-(Methylamino)ethyl]pyridine
Betahistina
 
Betahistinum
N-Methyl-2-(2-pyridinyl)ethanamine
N-Methyl-2-pyridineethanamine
[2-(2-Pyridyl)ethyl]methylamine
49
LisurideapprovedPhase 2518016-80-328864
Synonyms:
1,1-diethyl-3-[(8alpha)-6-methyl-9,10-didehydroergolin-8-yl]urea
18016-80-3
19875-60-6 (maleate (1:1))
3-(9,10-Didehydro-6-methylergolin-8alpha-yl)-1,1-diethylurea
AC1L1G87
BPBio1_000102
BSPBio_000092
C20H26N4O
CHEBI:51164
CHEMBL157138
CID28864
D08132
DB00589
EINECS 241-925-1
HMS1568E14
LISURIDE
LS-159312
Lisurid
Lisurida
Lisurida [INN-Spanish]
 
Lisuride
Lisuride (INN)
Lisuride (S)(-)
Lisuride Maleate (1:1)
Lisuride [INN]
Lisuridum
Lisuridum [INN-Latin]
Lopac0_000751
Lysurid
Lysuride
Lysuride Hydrogen Maleate
Methylergol Carbamide
MolPort-003-943-009
N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea
N'-((8alpha)-9,10-didehydro-6-methylergolin-8-yl)-N,N-diethylurea
Prestwick0_000106
Prestwick1_000106
Prestwick2_000106
Prestwick3_000106
Prestwick_525
SPBio_002031
UNII-E0QN3D755O
50
LevodopaapprovedPhase 238859-92-76047
Synonyms:
(-)-(3,4-Dihydroxyphenyl)alanine
(-)-3-(3,4-Dihydroxyphenyl)-L-alanine
(-)-3-(3,4-dihydroxyphenyl)-L-alanine
(-)-Dopa
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate
(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid
(−)-3-(3,4-dihydroxyphenyl)-L-alanine
(−)-dopa
.Beta.-(3, 4-Dihydroxyphenyl)alanine
.Beta.-(3,4-Dihydroxyphenyl)-L-alanine
1E83F927-C221-46AA-B90A-81B33C5F3868
2-Amino-3-(3,4-dihydroxyphenyl)propanoic acid
23734-74-9
25525-15-9
3, 4-Dihydroxy-L-phenylalanine
3, 4-Dihydroxyphenylalanine
3,4-DIHYDROXYPHENYLALANINE
3,4-Dihydroxy-L-phenylalanine
3,4-Dihydroxyphenyl-L-alanine
3,4-Dihydroxyphenylalanine
3,4-Dihydroxyphenylalanine (VAN)
3,4-dihydroxy-L-phenylalanine
3,4-dihydroxyphenylalanine
3-(3,4-Dihydroxypheny
3-(3,4-Dihydroxyphenyl)-L-alanine
3-Hydroxy-L-tyrosine
34241-25-3
37830_FLUKA
587-45-1
59-92-7
72572-99-7
72573-00-3
88250-23-1
90638-38-3
AC-11686
AC1L1LOR
AC1Q4U7F
BIDD:GT0158
BPBio1_000059
BSPBio_000053
BSPBio_002354
Bendopa
Bio-0575
Biodopa
Brocadopa
C00355
C9H11NO4
CAS-59-92-7
CCRIS 3766
CHEBI:15765
CHEMBL1009
CID6047
Cerepap
Cidandopa
D 9628
D00059
D0600
D9628
D9628_SIGMA
DAH
DB01235
DOPA
Deadopa
Dihydroxy-L-phenylalanine
Dihydroxyphenylalanine
DivK1c_000452
Dopa
Dopaflex
Dopaidan
Dopal
Dopal-Fher
Dopal-fher
Dopalina
Dopar
Dopar (TN)
Doparkine
Doparl
Dopasol
Dopaston
Dopaston SE
Dopastone
Dopastral
Dopicar
Doprin
EINECS 200-445-2
EU-0100454
Eldopal
Eldopar
Eldopatec
Eurodopa
HMS1568C15
HMS1922J14
HMS2090O08
HMS2093N04
HMS501G14
HSDB 3348
Helfo DOPA
 
Helfo-Dopa
Helfo-dopa
IDI1_000452
IV Levodopa
InChI=1/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14
Insulamina
KBio1_000452
KBio2_000934
KBio2_003502
KBio2_006070
KBioGR_001177
KBioSS_000934
L Dopa
L(-)-Dopa
L-(-)-Dopa
L-(3, 4-Dihydroxyphenyl)-.alpha.-alani
L-(3, 4-Dihydroxyphenyl)alanine
L-(o-Dihydroxyphenyl)alanine
L-.Beta.-(3,4-Dihydroxyphenyl)alanine
L-3,4-Dihydroxyphenylalanine
L-3,4-dihydroxyphenylalanine
L-3-(3,4-Dihydroxyphenyl)-Alanine
L-3-(3,4-Dihydroxyphenyl)alanine
L-3-Hydroxytyrosine
L-4-5-Dihydroxyphenylalanine
L-DOPA
L-DOPA, Parcopa, Atamet, Stalevo, Madopar, Prolopa, Dopar, 3,4-Dihydroxyphenylalanine, Levodopa
L-Dihydroxyphenylalanine
L-Dopa
L-O-Dihydroxyphenylalanine
L-b-(3,4-Dihydroxyphenyl)-a-alanine
L-beta-(3,4-Dihydroxyphenyl)-alpha-alanine
L-beta-(3,4-Dihydroxyphenyl)alanine
L-o-Hydroxytyrosine
LS-255
Laradopa
Larodopa
Ledopa
Levedopa
Levodopa
Levodopa (JP15/USP)
Levodopa (JP15/USP/INN)
Levodopa [USAN:INN:BAN:JAN]
Levodopum
Levodopum [INN-Latin]
Levopa
Lopac-D-9628
Lopac0_000454
MLS000028514
Maipedopa
MolPort-000-856-937
NCGC00015384-01
NCGC00016270-01
NCGC00016270-06
NCGC00093869-04
NINDS_000452
NSC 118381
NSC118381
PDSP1_001541
PDSP2_001525
Parda
Pardopa
Prestwick0_000017
Prestwick1_000017
Prestwick2_000017
Prestwick3_000017
Prestwick_185
Prodopa
Ro 4-6316
S1726_Selleck
SDCCGMLS-0066924.P001
SMR000058312
SPBio_000391
SPBio_001974
SPECTRUM2300205
Sobiodopa
Spectrum2_000496
Spectrum4_000539
Spectrum5_001899
Spectrum_000454
Syndopa
UNII-46627O600J
Veldopa
Weldopa
b-(3,4-Dihydroxyphenyl)-L-alanine
b-(3,4-Dihydroxyphenyl)-a-L-alanine
b-(3,4-Dihydroxyphenyl)alanine
beta-(3,4-Dihydroxyphenyl)-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-L-alanine
beta-(3,4-Dihydroxyphenyl)-alpha-alanine
beta-(3,4-Dihydroxyphenyl)alanine
bmse000322
component of Sinemet
l)-L-alanine
nchembio.2007.55-comp26
nchembio.89-comp9
ne
β-(3,4-dihydroxyphenyl)alanine

Interventional clinical trials:

(show top 50)    (show all 83)
idNameStatusNCT IDPhase
1Efficacy and Tolerability of Armodafinil in Adults With Excessive Sleepiness Associated With Shift Work DisorderCompletedNCT01080807Phase 4
2Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and DepressionCompletedNCT00518986Phase 4
3Study to Evaluate Armodafinil Treatment in Improving Prefrontal Cortical Activation and Working Memory PerformanceCompletedNCT00711516Phase 4
4Provigil in Conjunction With SSRIs for the Treatment of Mild or Moderate Depression With Attendant Symptoms of Sleepiness and Fatigue.CompletedNCT00208715Phase 4
5Neuroimaging Study of Bupropion Treatment in Patients With Major Depressive DisorderCompletedNCT01541475Phase 4
6Obstructive Sleep Apnea (OSA), Sleepiness, and Activity in Diabetes ManagementCompletedNCT00801892Phase 4
7An Eight Week, Double-Blind Efficacy Study of Armodafinil Augmentation to Alleviate Fibromyalgia FatigueCompletedNCT00678691Phase 4
8Effect of Armodafinil on Simulated DrivingNot yet recruitingNCT02468856Phase 4
9Palatal Implants in Combination With Continuous Positive Airway Pressure to Treat Obstructive Sleep ApneaTerminatedNCT00730041Phase 4
10Palliative Morphine With or Without Concurrent ModafinilUnknown statusNCT01766323Phase 3
11Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag DisorderCompletedNCT00758498Phase 3
12Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSDCompletedNCT00080288Phase 3
13Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With NarcolepsyCompletedNCT00107796Phase 3
14PROVIGIL® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeCompletedNCT00107848Phase 3
15Study of PROVIGIL ® (Modafinil) Treatment in Children and Adolescents With Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea SyndromeCompletedNCT00107809Phase 3
16Safety and Efficacy Study of Armodafinil (CEP-10953) in the Treatment of Excessive Sleepiness Associated With NarcolepsyCompletedNCT00078377Phase 3
17Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea (OSA/H) SyndromeCompletedNCT00079677Phase 3
18Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Obstructive Sleep Apnea/Hypopnea Syndrome(OSAHS)CompletedNCT00078325Phase 3
19Assess the Safety and Effectiveness of PROVIGIL Treatment in Children and Adolescents With Excessive SleepinessCompletedNCT00214968Phase 3
20Extension Study of the Safety and Efficacy of Armodafinil in the Treatment of Patients With Excessive SleepinessCompletedNCT00228553Phase 3
21Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea SyndromeCompletedNCT00228566Phase 3
22Armodafinil (CEP-10953) for Treatment of Narcolepsy, Obstructive Sleep Apnea/Hypopnea Syndrome, or Chronic Shift Work Sleep DisorderCompletedNCT00078312Phase 3
23Caffeine for Excessive Daytime Somnolence in Parkinson's DiseaseCompletedNCT00459420Phase 2, Phase 3
24Efficacy and Safety of DHEA for Myotonic DystrophyCompletedNCT00167609Phase 2, Phase 3
25Study of the Efficacy and Multiple-Dose Plasma Concentration-Time Profiles of Armodafinil and PROVIGILCompletedNCT00236080Phase 3
26Effects of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy.CompletedNCT01638403Phase 3
27"Six-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"Active, not recruitingNCT02348619Phase 3
28"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"Active, not recruitingNCT02348606Phase 3
29"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in Narcolepsy"Active, not recruitingNCT02348593Phase 3
30"A Long-Term Safety Study of JZP-110 in the Treatment of Excessive Sleepiness in Subjects With Narcolepsy or OSA"Enrolling by invitationNCT02348632Phase 3
31Study to Evaluate the Safety, Tolerability, and Efficacy of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain InjuryTerminatedNCT00983437Phase 3
32Study to Evaluate the Efficacy and Safety of Armodafinil as Treatment for Patients With Excessive Sleepiness Associated With Mild or Moderate Closed Traumatic Brain InjuryTerminatedNCT00893789Phase 3
33Clarithromycin for the Treatment of HypersomniaCompletedNCT01146600Phase 2
34Flumazenil for the Treatment of Primary HypersomniaCompletedNCT01183312Phase 1, Phase 2
35VSF-173 Study in Healthy Adult Volunteers for Treatment of Induced Excessive SleepinessCompletedNCT00467441Phase 2
36Pilot Study of Melatonin and EpilepsyCompletedNCT00965575Phase 2
37Pilot Study of Betahistine Dihydrochloride in the Treatment of Major Depression With Atypical FeaturesCompletedNCT00585585Phase 2
38A Phase II Study of Minocycline and Armodafinil for Reducing the Symptom Burden Produced by Chemoradiation Treatment for Esophageal CancerCompletedNCT01746043Phase 2
39Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse HistoriesCompletedNCT00247572Phase 2
40Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant AbuseCompletedNCT00248092Phase 1, Phase 2
41Riluzole to Treat Major DepressionCompletedNCT00026052Phase 2
42Chloral Hydrate to Perform Auditory Brainstem Response (ABR)CompletedNCT00949780Phase 2
43Lisuride Patch to Treat Parkinson's DiseaseCompletedNCT00089622Phase 2
44A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2RecruitingNCT02512588Phase 2
45Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in NarcolepsyRecruitingNCT02806908Phase 2
46Study Assessing Effects of JZP-110 on Driving Performance in the Treatment of Excessive Sleepiness in OSARecruitingNCT02806895Phase 2
47Riluzole to Treat Depression in Bipolar DisorderTerminatedNCT00054704Phase 2
48Double-Blind Placebo-Controlled Trial of Riluzole in Pediatric Bipolar DisorderTerminatedNCT00805493Phase 2
49Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Armodafinil in Children and Adolescents With Excessive Sleepiness Associated With NarcolepsyCompletedNCT01624480Phase 1
50Amylase and HypersomniaUnknown statusNCT01926405

Search NIH Clinical Center for Hypersomnia

Genetic Tests for Hypersomnia

About this section

Anatomical Context for Hypersomnia

About this section

MalaCards organs/tissues related to Hypersomnia:

36
Brain, Testes, Heart, Hypothalamus, Eye, Pituitary, Thalamus

Publications for Hypersomnia

About this section

Articles related to Hypersomnia:

(show top 50)    (show all 339)
idTitleAuthorsYear
1
Disorders of Excessive Daytime Sleepiness Including Narcolepsy and Idiopathic Hypersomnia. (27542882)
2016
2
Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review. (26847972)
2016
3
Migraine with brainstem aura presenting as recurrent hypersomnia (Kleine-Levin syndrome). (27343267)
2016
4
The effects of Transcranial Direct Current Stimulation (tDCS) on Idiopathic Hypersomnia: a pilot study. (27548094)
2016
5
Post-stroke hypersomnia. (26763039)
2016
6
Idiopathic Hypersomnia and Hypersomnolence Disorder: A Systematic Review of the Literature. (26895727)
2016
7
Behavioral Sleep Medicine Services for Hypersomnia Disorders: A Survey Study. (26788889)
2016
8
Menstruation-Related Hypersomnia Treated with Hormonal Contraception: Case Report and Review of Literature. (26932284)
2016
9
Urine Toxicology in Adults Evaluated for a Central Hypersomnia and How the Results Modify the Physician's Diagnosis. (27568897)
2016
10
Recovery of Hypersomnia Concurrent With Recovery of an Injured Ascending Reticular Activating System in a Stroke Patient: A Case Report. (26765455)
2016
11
Posterior reversible encephalopathy syndrome of the midbrain and hypothalamus - a case report of uremic encephalopathy presenting with hypersomnia]. (26640128)
2016
12
French consensus. Idiopathic hypersomnia: Investigations and follow-up. (27838089)
2016
13
Diurnal and nocturnal cardiovascular variability and heart rate arousal response in idiopathic hypersomnia. (27810179)
2016
14
Hypersomnia as the first presentation in a patient with insulinoma: A case report and review of the literature. (27699047)
2016
15
Evaluation of polygenic risks for narcolepsy and essential hypersomnia. (27305985)
2016
16
Injury of the Ascending Reticular Activating System in Patients With Fatigue and Hypersomnia Following Mild Traumatic Brain Injury: Two Case Reports. (26871783)
2016
17
Central Hypersomnia. (26072339)
2015
18
Recurrent hypersomnia in an 18-year old boy: CSF hypocretin level and MSLT findings. (26323648)
2015
19
Characteristics of patients with hypersomnia by actigraphy. (25818262)
2015
20
Hypersomnia subtypes, sleep and relapse in bipolar disorder. (25515854)
2015
21
Narcolepsy with and without cataplexy, idiopathic hypersomnia with and without long sleep time: a cluster analysis. (25576137)
2015
22
Central Disorders of Hypersomnolence: Focus on the Narcolepsies and Idiopathic Hypersomnia. (26149554)
2015
23
Hypersomnia in Mood Disorders: a Rapidly Changing Landscape. (26258003)
2015
24
IL-1I^ and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder. (26241349)
2015
25
Neuromyelitis optica spectrum disorder presenting with repeated hypersomnia due to involvement of the hypothalamus and hypothalamus-amygdala linkage. (25680985)
2015
26
Recurrent hypersomnia: Report of medication-responsive cases. (26483951)
2015
27
An association analysis of HLA-DQB1 with narcolepsy without cataplexy and idiopathic hypersomnia with/without long sleep time in a Japanese population. (27081540)
2015
28
Evaluation of the Effect of Modafinil on Cognitive Functions in Patients with Idiopathic Hypersomnia with P300. (26116438)
2015
29
Bifrontal Anodal Transcranial Direct Current Stimulation (tDCS) Improves Daytime Vigilance and Sleepiness in aA Patient With Organic Hypersomnia Following Reanimation. (26077954)
2015
30
Smoking, Alcohol, Drug Use, Abuse and Dependence in Narcolepsy and Idiopathic Hypersomnia: A Case-Control Study. (26564129)
2015
31
Response to the letter to the editor from Dr. Kawada, "Characteristics of patients with hypersomnia by actigraphy". (25818261)
2015
32
Misdiagnosis of menstruation-related recurrent hypersomnia as epilepsy in a patient with generalized epileptic discharges. (25878739)
2015
33
Idiopathic hypersomnia. (26599679)
2015
34
The Prevalence and Characteristics of Primary Headache and Dream-Enacting Behaviour in Japanese Patients with Narcolepsy or Idiopathic Hypersomnia: A Multi-Centre Cross-Sectional Study. (26418536)
2015
35
CDH13 and HCRTR2 May Be Associated with Hypersomnia Symptom of Bipolar Depression: A Genome-Wide Functional Enrichment Pathway Analysis. (26207136)
2015
36
Sleepiness and Performance Is Disproportionate in Patients with Non-Organic Hypersomnia in Comparison to Patients with Narcolepsy and Mild to Moderate Obstructive Sleep Apnoea. (25377356)
2014
37
Modafinil in the treatment of idiopathic hypersomnia without long sleep time-a randomized, double-blind, placebo-controlled study. (25196321)
2014
38
Use of subcutaneous flumazenil preparations for the treatment of idiopathic hypersomnia: A case report. (24554692)
2014
39
Infantile epileptic encephalopathy, transient choreoathetotic movements, and hypersomnia due to a De Novo missense mutation in the SCN2A gene. (24710820)
2014
40
Diffusion tensor imaging in a patient with cerebral palsy and hypersomnia. (24269132)
2014
41
Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review. (24854887)
2014
42
Altered dynamics in the circadian oscillation of clock genes in dermal fibroblasts of patients suffering from idiopathic hypersomnia. (24454829)
2014
43
Prevalence and clinical correlates of co-occurring insomnia and hypersomnia symptoms in depression. (24953480)
2014
44
Unusual presentation of hypothalamic hamartoma with hypersomnia in an adult patient. (25042667)
2014
45
Manual characterization of sleep spindle index in patients with narcolepsy and idiopathic hypersomnia. (24800086)
2014
46
A case of herpes simplex encephalitis with hypersomnia and low orexin level in the cerebrospinal fluid. (24705834)
2014
47
Usefulness of genetic characterization of narcolepsy and hypersomnia on phenotype definition: a study in Portuguese patients. (24399620)
2014
48
NREM sleep hypersomnia and reduced sleep/wake continuity in a neuroendocrine mouse model of anxiety/depression based on chronic corticosterone administration. (24909899)
2014
49
Cortical-subcortical interactions in hypersomnia disorders: mechanisms underlying cognitive and behavioral aspects of the sleep-wake cycle. (25309500)
2014
50
Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial. (24587570)
2014

Variations for Hypersomnia

About this section

Expression for genes affiliated with Hypersomnia

About this section
Search GEO for disease gene expression data for Hypersomnia.

Pathways for genes affiliated with Hypersomnia

About this section

Pathways related to Hypersomnia according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.8HLA-DRB1, TRA
29.3HLA-DQB1, HLA-DRB1, PTPA

GO Terms for genes affiliated with Hypersomnia

About this section

Cellular components related to Hypersomnia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1MHC class II protein complexGO:004261310.1HLA-DQB1, HLA-DRB1

Biological processes related to Hypersomnia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1positive regulation of transmission of nerve impulseGO:005197110.3CARTPT, HCRT
2regulation of neurotransmitter secretionGO:004692810.0HCRT, PARK2
3chemical synaptic transmissionGO:00072689.7CARTPT, HCRT, HCRTR1, PMCH
4neuropeptide signaling pathwayGO:00072189.6CARTPT, HCRT, HCRTR1, PMCH

Sources for Hypersomnia

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet